Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report

BACKGROUND: Emicizumab is a novel prophylactic medication used to treat patients with hemophilia A. It is indicated to minimize the frequency of bleeding episodes and the severity of serious bleeding in patients with hemophilia A utilizing inhibitors. However, some cases of bleeding episodes have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Albattat, Sami, Alabdultaif, Abbas, Albattat, Fatimah, Albattat, Batla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948523/
https://www.ncbi.nlm.nih.gov/pubmed/36814352
http://dx.doi.org/10.1186/s13256-023-03783-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948523/
https://www.ncbi.nlm.nih.gov/pubmed/36814352
http://dx.doi.org/10.1186/s13256-023-03783-7

Ejemplares similares